Rhein sensitizes human pancreatic cancer cells to EGFR inhibitors by inhibiting STAT3, providing an innovative framework for pancreatic cancer treatment, especially in combination with EGFR inhibitors [60]. The gene discussed is STAT3; the disease is familial pancreatic carcinoma.